Sherene Loi, Medical Oncologist, Lab Head of Breast Oncology Clinical Trials at Peter MacCallum Cancer Centre, Australia, shared a post by Paolo Tarantino, adding:
“DB-11: interesting that pCR increased from 11% to 67%, IMO not that impressive to what we’ve seen before- but less cardiac toxicity.
Pity the comparator wasn’t TCHP – let’s wait to see pCR rates by ER status and HER2+ 2 versus +3 IHC. EFS however looks very interesting at 0.56 (immature)- will be interesting to compare to DB-05. ”
Quoting Paolo Tarantino‘s post:
“DB-11 abstract just released. In high-risk (more than T3, N positive, or IBC) HER2 positive eBC, neoadjuvant T-DXd-THP outperformed ddAC-THP (pCR rate 67% versus 56%, p=0.003), with reduction in cardiotoxicity (LVD 1.9 versus 9%) and low rate of ILD (4.4 versus 5.1%). The last nail in the coffin for anthracyclines.”
More posts featuring Paolo Tarantino and Sherene Loi on OncoDaily.